Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.
Search results for:

lanreotide

lanreotide
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Somatuline Depot SOLUTION, SUBCUTANEOUS 60 mg/0.2 mL, 90 mg/0.3 mL, 120 mg/0.5 mL    
Comments:

ORDERED FORMULATION

THERAPEUTIC INTERCHANGE

lanreotide (Somatuline Depot)

  • 60 mg Monthly
  • 90 mg Monthly
  • 120 mg Monthly

octreotide (SandoSTATIN)

  • 50 mcg QID
  • 100 mcg QID
  • 200 mcg QID

Somatuline Depot is a monthly subcutaneous injection of a somastatin analog for long term treatment of acromegly. It is classified as formulary, restricted to outpatient use.

For Inpatients: See if therapy can be deferred until after hospital discharge. If not, convert to immediate release octreotide injection.

 

For Updated Formulary Preferred Products (Inpatient and Outpatient): Preferred Products for Select Agents 

Reviewed: June 24, 2008

Last updated: Mar. 19, 2024






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2024 Rpharmy, LLC ­ All Rights Reserved